Tianran WANG, Zhiqiang NIE, Hao ZOU, et al. Ginsenoside Rg1 promotes endothelialization of tissue-engineered blood vessels in transplanted rats[J]. Journal of Third Military Medical University, 2020, 42(5): 444-452.
DOI:
Tianran WANG, Zhiqiang NIE, Hao ZOU, et al. Ginsenoside Rg1 promotes endothelialization of tissue-engineered blood vessels in transplanted rats[J]. Journal of Third Military Medical University, 2020, 42(5): 444-452. DOI: 10.16016/j.1000-5404.201909178.
Ginsenoside Rg1 promotes endothelialization of tissue-engineered blood vessels in transplanted rats
To prepare the endothelialization-promoting tissue-engineered blood vessels (TEBVs) with encapsulated Ginsenoside Rg1 (Rg1) to promote endothelialization
and to evaluate its patency and endothelialization after implantation into the rat common carotid artery.
Methods
2
CCK-8 assay and flow cytometry were used to detect the effects of Rg1 on the proliferation and apoptosis of endothelial cells (ECs) after 48 hours' treatment
and the optimal dose of the agent was also determined. ECs was divided into control group
Rg1 treatment group (15.63 μmol/L Rg1)
and Rg1+XL184 (15.63 μmol/L Rg1+0.5 μg/mL XL184
VEGFR2 inhibitor) treatment group. Cell proliferation and wound healing of ECs were examined after the treatment for 48 h. Chitosan coated Rg1-(2-hydroxypropyl)-cyclodextrin particles (Rg1-HGC/CS NPs
abbreviated as NPs) were prepared and modified to the lumen of blood vessels (after decellularization and collagen treatment)
and then Fourier transform infrared (FTIR) spectroscopy
dynamic light scattering (DLS) and scanning electron microscopy (SEM) were used to detect these obtained samples. ECs were co-cultured with acellular vessels and TEBVs for 48 h to observe the biocompatibility. For
in vivo
study
the acellular vessels were divided into collagen group (collagen treatment)
blank CS group (collagen and chitosan treatment)
and NPs group (modified with NPs). Then these vessel samples were transplanted into the left common carotid artery of SD rats respectively. Ultrasound and micro-CT scanning were performed to observe the vascular patency in 30 and 90 d after transplantation. HE and Masson staining and immunofluorescence assay for CD31 and vWF were used to observe the endothelialization in each group in 90 d after transplantation.
Results
2
Rg1 promoted the proliferation and migration of ECs
via
VEGFR2 (
P
<
0.05)
and showed no significant effect on apoptosis. The prepared NPs were about 130 nm in diameter and uniform in shape (PDI
<
0.3)
and could be successfully modified to the lumen of blood vessels. The co-cultured study showed that endothelialization-promoting TEBVs displayed better biocompatibility for favorable of cell adhesion and growth. In 30 and 90 d after transplantation
radiological studies displayed that the NPs-treated vessels showed better vascular patency than the other groups. HE and Masson staining indicated that in 90 d after transplantation
the collagen and blank CS groups had blood vessels deformed
without normal structures and blocked due to the thrombosis and collagen fibrosis
while the NPs group had intact blood vessels and better patency. Immunofluorescence assay for CD31 and vWF showed that the lumen in the vessles from the NPs group had ECs well-covered
suggesting better endothelialization when compared with other groups.
Conclusion
2
Endothelialization-promoting TEBVs shows better promoting effect on endothelialization
and is helpful in maintenance of long-term patency of blood vessels after transplantation.
关键词
Keywords
references
DAHL S L, KYPSON A P, LAWSON J H, et al . Readily available tissue-engineered vascular grafts[J ] . Sci Transl Med, 2011, 3(68): 68ra9. DOI:10.1126/scitranslmed.3001426.
GAUDINO M, ANTONIADES C, BENEDETTO U, et al . Mechanisms, consequences, and prevention of coronary graft failure[J ] . Circulation, 2017, 136(18): 1749-1764. DOI:10.1161/CIRCULATIONAHA.117.027597.
RATCLIFFE A. Tissue engineering of vascular grafts[J]. Matrix Biol, 2000, 19(4): 353-357. DOI:10.1016/s0945-053x(00)00080-9.
MEDZHITOV R. Inflammation 2010: new adventures of an old flame[J]. Cell, 2010, 140(6): 771-776. DOI:10.1016/j.cell.2010.03.006.
SEIFU D G, PURNAMA A, MEQUANINT K, et al . Small-diameter vascular tissue engineering[J ] . Nat Rev Cardiol, 2013, 10(7): 410-421. DOI:10.1038/nrcardio.2013.77.
SONG H G, RUMMA R T, OZAKI C K, et al . Vascular tissue engineering: progress, challenges, and clinical promise[J ] . Cell Stem Cell, 2018, 22(3): 340-354. DOI:10.1016/j.stem.2018.02.009.
VAN HINSBERGH V W. Endothelium: role in regulation of coagulation and inflammation[J]. Semin Immunopathol, 2012, 34(1): 93-106. DOI: 10.1007/s00281-011-0285-5.
SERBO J V, GERECHT S. Vascular tissue engineering: biodegradable scaffold platforms to promote angiogenesis[J]. Stem Cell Res Ther, 2013, 4(1): 8. DOI:10.1186/scrt156.
MELCHIORRI A J, HIBINO N, FISHER J P. Strategies and techniques to enhance the in situ endothelialization of small-diameter biodegradable polymeric vascular grafts[J ] . Tissue Eng Part B Rev, 2013, 19(4): 292-307. DOI:10.1089/ten.TEB.2012.0577.
WU X D, GUO T, LIU L, et al . MiR-23a targets RUNX2 and suppresses ginsenoside Rg1-induced angiogenesis in endothelial cells[J ] . Oncotarget, 2017, 8(35): 58072-58085. DOI:10.18632/oncotarget.19489.
SENGUPTA S, TOH S A, SELLERS L A, et al . Modulating angiogenesis: the Yin and the Yang in ginseng[J ] . Circulation, 2004, 110(10): 1219-1225. DOI: 10.1161/01.CIR.0000140676.88412.CF.
LEUNG K W, NG H M, TANG M K, et al . Ginsenoside-Rg1 mediates a hypoxia-independent upregulation of hypoxia-inducible factor-1α to promote angiogenesis[J ] . Angiogenesis, 2011, 14(4): 515-522. DOI:10.1007/s10456-011-9235-z.
YANCOPOULOS G D, DAVIS S, GALE N W, et al . Vascular-specific growth factors and blood vessel formation[J ] . Nature, 2000, 407(6801): 242-248. DOI:10.1038/35025215.
VEIKKOLA T, ALITALO K. VEGFs, receptors and angiogenesis[J]. Semin Cancer Biol, 1999, 9(3): 211-220. DOI:10.1006/scbi.1998.0091.
YANG J Y, WEI K Y, WANG Y Q, et al . Construction of a small-caliber tissue-engineered blood vessel using icariin-loaded β-cyclodextrin sulfate for in situ anticoagulation and endothelialization[J ] . Sci China Life Sci, 2018, 61(10): 1178-1188. DOI:10.1007/s11427-018-9348-9..
REKHARSKY M V, INOUE Y.Complexation thermodynamics of cyclodextrins[J]. Chem Rev, 1998, 98(5): 1875-1918. DOI:10.1021/cr970015o.
SZEJTLI J. Medicinal applications of cyclodextrins[J]. Med Res Rev, 1994, 14(3): 353-386. DOI:10.1002/med.2610140304.
UEKAMA K. Design and evaluation of cyclodextrin-based drug formulation[J]. Chem Pharm Bull, 2004, 52(8): 900-915. DOI:10.1248/cpb.52.900.
UEKAMA K, HIRAYAMA F, IRIE T. Cyclodextrin drug carrier systems[J]. Chem Rev, 1998, 98(5): 2045-2076. DOI:10.1021/cr970025p.
CHAN R Y, CHEN W F, DONG A, et al . Estrogen-like activity of ginsenoside Rg1 derived from Panax notoginseng[J ] . J Clin Endocrinol Metab, 2002, 87(8): 3691-3695. DOI:10.1210/jcem.87.8.8717.
LU X Z, WANG J H, WU X, et al . Ginsenoside Rg1 promotes bone marrow stromal cells proliferation via the activation of the estrogen receptor-mediated signaling pathway[J ] . Acta Pharmacol Sin, 2008, 29(10): 1209-1214. DOI:10.1111/j.1745-7254.2008.00874.x..
BUTTAFOCO L, ENGBERS-BUIJTENHUIJS P, POOT A A, et al . Physical characterization of vascular grafts cultured in a bioreactor[J ] . Biomaterials, 2006, 27(11): 2380-2389. DOI:10.1016/j.biomaterials.2005.10.017.